Clinical Trials
14 trialsNCT00550615 2023-09-26
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00869401 2020-02-13
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00820170 2019-08-13
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00826449 2016-06-28
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01218477 2016-06-17
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00850382 2016-03-01
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
University of Ulm
Phase 1/2 Completed
NCT00924352 2014-10-13
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00439270 2014-03-28
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00597038 2013-12-16
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00337454 2011-04-14
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00482703 2010-12-17
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01030718 2010-12-14
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Bristol-Myers Squibb
Phase 1/2 Completed